Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Sponsor: Merck Sharp & Dohme LLC

Conditions: Prostate Cancer Metastatic

Interventions: Opevesostat, Abiraterone acetate, Enzalutamide, Hydrocortisone, Fludrocortisone acetate

Countries: United States, Argentina, Australia, Austria, Brazil, Canada, Chile, China

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) in participants with mCRPC previously treated with next-generation hormonal agent (NHA) and taxane-based chemotherapy. It is hypothesized that opevesostat is superior with respect to OS in androgen receptor ligand binding domain (AR LBD) mutation-negative and -positive participants.